Skip to main content

Free Content Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran

Download Article:
(PDF 265.91796875 kb)
BACKGROUND: Smoking cessation programmes were first introduced in Iran in 1997. To date a number of types of nicotine replacement therapy have been prescribed.

OBJECTIVE: To evaluate the effectiveness of varenicline for tobacco cessation.

METHODS: This was a randomised parallel clinical study conducted in 2010. Participants were smokers willing to quit who were visiting a smoking cessation clinic for the first time and were randomly divided into three groups: all three groups received brief counselling on cessation, Group 2 received nicotine patches and Group 3 was prescribed varenicline for 8 weeks.

RESULTS: There were 272 participants in the study: 91 in Group 1, 92 in Group 2 and 89 in Group 3. At the end of the first month, 128 of the 272 subjects (47.1%) succeeded in quitting: 17 (18.7%) in Group 1, 60 (65.2%) in Group 2 and 51 (57.3%) in Group 3 (P = 0.000). At follow-up after 12 months, 58 subjects (21.3%) remained smoke-free, of whom 6 (6.6%) were in Group 1, 23 (25%) in Group 2 and 29 (32.6%) in Group 3 (P = 0.000).

CONCLUSION: In the study, varenicline treatment was slightly more effective than but not significantly different from nicotine replacement therapy.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: medication therapy management; smoking cessation; varenicline

Document Type: Research Article

Affiliations: 1: Tobacco Prevention & Control Research Centre, Tehran, Iran 2: National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Publication date: 2012-02-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more